Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07266805 · ClinicalTrials.gov registry record · Phase 3
Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant IR Capsule for On-Demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor Deficiency
A Phase 3 study of Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH), sponsored by Pharvaris Netherlands B.V..
- Recruiting
- Registry status
- Phase 3
- Development phase
- 32
- Enrollment target
- 7
- Study locations
NCT07266805: Recruiting Phase 3 study of Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH), sponsored by Pharvaris Netherlands B.V..
NCT07266805 is a Phase 3 study of Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH) that is actively recruiting participants, run by Pharvaris Netherlands B.V.. The registered enrollment target is 32 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (96% lower). The trial reports 7 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07266805, a Phase 3 study of Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH), is actively recruiting participants, sponsored by Pharvaris Netherlands B.V..
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 32 participants
- Enrollment target
- 7
- Study locations
Study Summary
This is a Phase 3, multicenter, 3-part study, with 2 randomized, double-blind, placebo-controlled parts and an open-label extension part, to evaluate the efficacy and safety of orally administered deucrictibant XR tablet for prophylaxis, and deucrictibant IR capsule for on-demand treatment of angioedema attacks in adult participants aged ≥ 18 years with AAE-C1INH.
Primary Outcome
Time-normalized number of Investigator-confirmed AAE attacks during Treatment Phase
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Deucrictibant
Study Locations (7)
Other
- Study Site - Edmonton
- Study Site - Cambridge
- Study Site - Leicester
- Study Site - London
- Study Site - Plymouth
California
- Study Site - Walnut Creek
Missouri
- Study Site - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2025-10-16 |
| Est. Completion | 2027-06 |
| Phase | Phase 3 |
What NCT07266805 shows while recruiting
NCT07266805 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07266805 lists 7 locations in 3 states (Other, California, Missouri).
Frequently Asked Questions
What is clinical trial NCT07266805 about?
NCT07266805 is a clinical study titled "Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant IR Capsule for On-Demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor Deficiency". This is a Phase 3, multicenter, 3-part study, with 2 randomized, double-blind, placebo-controlled parts and an open-label extension part, to evaluate the efficacy and safety of orally administered deucrictibant XR tablet for prophylaxis, and deucrictibant IR capsule for on-demand treatment of angioe...
What is the current status of trial NCT07266805?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 32 participants. The study started on 2025-10-16. Estimated completion is 2027-06.
What conditions does trial NCT07266805 study?
This clinical trial studies the following conditions: Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH).
What interventions are being tested in trial NCT07266805?
The interventions under investigation include: Placebo (DRUG), Deucrictibant (DRUG).
Who is sponsoring clinical trial NCT07266805?
This trial is sponsored by Pharvaris Netherlands B.V., which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07266805 being conducted?
This trial has 7 study locations across California, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07266805's enrollment target sits among peer trials
32 1910th of 2000 higher than 87 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI